Polymer Medical Launches in Western New York by Two Industry Leaders

Polymer Medical Inc.

Plastics industry veterans Benjamin Harp and Tom Rybicki have launched Polymer Medical Inc. to provide healthcare and biosciences clients with contract injection-molding and assembly services. The new company’s focus will be producing critical drug-delivery systems, medical disposables like syringes, medical devices for home healthcare to orthopedics, specialty packaging, and pharmaceutical disposables among other services. Harp and Rybicki each have decades of experience founding and operating plastics industry manufacturers for healthcare, pharmaceuticals, and nutraceuticals.

Benjamin Harp, Polymer Medical President

“There’s a rising demand for medical devices partly because of changes in demographics and approaches to home healthcare; the time is right for a new entrant like Polymer Medical. Our knowledge of the specifications and science of producing polymers for healthcare and bioscience along with what we understand about delivering product quality and innovation give us a competitive edge.”

Polymer Market to Grow

According to an array of analyst reports, researchers expect the medical polymers market to grow at a compound annual growth rate of more than five percent through 2030, reaching more than $30 billion. Harp and Rybicki also believe North American customers are more eager than before the pandemic to favor U.S.-based providers for their supply chain. The field is already packed with competition, but Harp and Rybicki see Polymer Medical’s creativity, design know-how, process control, and tooling expertise as critical differentiators.

Tom Rybicki, vice president of Operations for Polymer Medical

“When a client comes to us, we’ll provide Design for Manufacturing analysis to offer ways to improve on what they’re already trusting us to make. When we take an order from a customer, we assess their tool, or mold, for those big or small things that could disrupt production. That saves money for the customer and ensures quality.”

Investment In Management Systems

Quality is a centerpiece for Polymer Medical, which is why Harp says the new company has invested in its quality management systems, in part, to meet ISO 13485:2016 standards for medical devices. After analysis by Polymer Medical’s degreed engineers and RJG Master Molder® qualified technicians and managers, Harp’s employees will produce customers’ designs in ISO-7 and ISO-8 clean manufacturing environments. The company also provides cleanroom assembly and packaging.

“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.”

Polymer Medical’s newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”